175 related articles for article (PubMed ID: 27373893)
1. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data.
Pratt AG; Lendrem D; Hargreaves B; Aslam O; Galloway JB; Isaacs JD
Rheumatology (Oxford); 2016 Oct; 55(10):1843-8. PubMed ID: 27373893
[TBL] [Abstract][Full Text] [Related]
2. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
4. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
Kolarz B; Majdan M; Dryglewska M; Darmochwal-Kolarz D
Rheumatol Int; 2011 Nov; 31(11):1439-43. PubMed ID: 20473501
[TBL] [Abstract][Full Text] [Related]
6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
7. Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis.
Reid AB; Wiese M; McWilliams L; Metcalf R; Hall C; Lee A; Hill C; Wechalekar M; Cleland L; Proudman SM
Intern Med J; 2020 Jul; 50(7):818-822. PubMed ID: 32656986
[TBL] [Abstract][Full Text] [Related]
8. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
Aletaha D; Alasti F; Smolen JS
Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
[TBL] [Abstract][Full Text] [Related]
11. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study.
Ursum J; Bos WH; van Dillen N; Dijkmans BA; van Schaardenburg D
Arthritis Res Ther; 2010; 12(1):R8. PubMed ID: 20064278
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
13. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
Boeters DM; Trouw LA; van der Helm-van Mil AHM; van Steenbergen HW
Arthritis Res Ther; 2018 May; 20(1):94. PubMed ID: 29724250
[TBL] [Abstract][Full Text] [Related]
14. Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
Alemao E; Bao Y; Weinblatt ME; Shadick N
Arthritis Care Res (Hoboken); 2020 Feb; 72(2):176-183. PubMed ID: 31529682
[TBL] [Abstract][Full Text] [Related]
15. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.
Barra LJ; Pope JE; Hitchon C; Boire G; Schieir O; Lin D; Thorne CJ; Tin D; Keystone EC; Haraoui B; Jamal S; Bykerk VP;
Rheumatology (Oxford); 2017 May; 56(5):768-776. PubMed ID: 28073956
[TBL] [Abstract][Full Text] [Related]
16. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.
Boeters DM; Burgers LE; Sasso EH; Huizinga TWJ; van der Helm-van Mil AHM
Arthritis Res Ther; 2019 May; 21(1):121. PubMed ID: 31088574
[TBL] [Abstract][Full Text] [Related]
17. The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia.
Ten Brinck RM; van Steenbergen HW; van Delft MAM; Verheul MK; Toes REM; Trouw LA; van der Helm-van Mil AHM
Rheumatology (Oxford); 2017 Dec; 56(12):2145-2153. PubMed ID: 28968865
[TBL] [Abstract][Full Text] [Related]
18. TLR1/2 and 5 induce elevated cytokine levels from rheumatoid arthritis monocytes independent of ACPA or RF autoantibody status.
Thwaites RS; Unterberger S; Chamberlain G; Walker-Bone K; Davies KA; Sacre S
Rheumatology (Oxford); 2020 Nov; 59(11):3533-3539. PubMed ID: 32594150
[TBL] [Abstract][Full Text] [Related]
19. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
20. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.
Ajeganova S; van Steenbergen HW; Verheul MK; Forslind K; Hafström I; Toes RE; Huizinga TW; Svensson B; Trouw LA; van der Helm-van Mil AH
Ann Rheum Dis; 2017 Jan; 76(1):112-118. PubMed ID: 27117699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
